Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
about
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyGlatiramer acetate for multiple sclerosisAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis.New developments in the treatment of optic neuritis.Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Escalating immunotherapy of multiple sclerosis.Chemotherapeutics in the treatment of multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumabTargeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trialTreatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.Induction therapy for patients with multiple sclerosis: why? When? How?A study of patients with aggressive multiple sclerosis at disease onset.Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.Managing MS in a changing treatment landscape.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.Multiple sclerosis: basic knowledge and new insights in perioperative management.Established and novel disease-modifying treatments in multiple sclerosis.The current role of mitoxantrone in the treatment of multiple sclerosis.Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.Characterising aggressive multiple sclerosis.Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion.Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
P2860
Q22241650-C67DFF0C-396F-4DB2-AB57-CA596F316E2FQ24235498-B7706605-3180-4B16-8F2E-5052421DA414Q30808014-31D8C856-81CD-44F4-A390-5A2085A85022Q33702072-E5EF807A-B037-47CC-B78B-61812CA5B0D0Q33899881-F3E677DC-67F2-456D-927C-14E58C33100EQ34409100-041CA048-F1C8-4C6B-912C-4A6E76165E71Q34409536-5FC34D7E-AD3F-4E27-A2D8-D868F51BF0E7Q34478828-DAE6C359-35F2-4FED-9C91-62F7DB6648C2Q35205472-CEAA3D3A-BEB8-46A5-B261-1423DC225265Q35295564-FB541390-1706-4C13-A400-7F0A2B350A36Q35544804-9D1C890C-1426-435A-BF89-001C9E342673Q35654037-4AEA64F0-DE05-423D-9FCB-51545A603359Q36923587-56BB3088-13C4-4F98-9AD9-4167B884479FQ37154936-A428243C-C711-49AA-AB1B-241FDA8385A0Q37200093-718F547B-EE4E-41C8-950B-C5349EBD5CC8Q37614062-9A069C33-8261-4211-BD12-2DB34CB2B45CQ37857752-99817368-8150-4949-8E36-B787E1D548EDQ37976344-CAD15EE0-80D4-4917-B8AF-02442A00E0B0Q38051577-AAB7E305-2B64-4AC4-B6DD-94EC1B2CDDB9Q38058831-8A464614-F57D-4A4B-AAF2-433C5F62B081Q38083041-BD4CBF83-628F-4ED4-AFDA-837A4A374368Q38130445-7E725462-8262-47D1-BB72-94B13F7FF491Q38180157-4880E709-EA3D-460F-AEFD-D61E56C389A9Q38212259-CC1D8812-8D92-4E9D-ADBC-994E32B50DC8Q40628996-5BCFB6B1-4386-4A50-8343-0164807A3C5CQ41447681-7B3116EB-CBE9-4D2F-88B7-8B51AC0897D6Q42920232-28B16075-6D91-42B6-AA6B-4BF032D3EA35Q42929708-52047F53-5518-4ABD-BEDF-509485E44E53Q43442571-3F562A68-03EB-4E40-803D-0E4FF2E8C00CQ45145307-9D5B517C-627B-4B2D-A00A-1F91779D8130Q46104696-6F573AAF-CEDC-4B33-A4A7-893205DA8583Q46431006-31E74BEB-CF5B-4EBD-8F36-70CE0CF52A53Q47926720-31AFD8D6-33F0-4D7F-BDC1-5850449B42B1Q51274361-5CD534E6-2C8D-4636-959D-A213187B463F
P2860
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@en
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@nl
type
label
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@en
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@nl
prefLabel
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@en
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@nl
P2093
P356
P1476
Mitoxantrone as induction trea ...... y of 100 consecutive patients.
@en
P2093
Emmanuelle Le Page
Emmanuelle Leray
Gilles Edan
Grégory Taurin
Jacques Chaperon
Marc Coustans
Sean P Morrissey
P356
10.1136/JNNP.2007.124958
P407
P577
2007-09-10T00:00:00Z